Domain Therapeutics

Strasbourg, France Founded: 2008 • Age: 18 yrs
GPCR-targeted drug candidates for immuno-oncology and inflammation are developed.

About Domain Therapeutics

Domain Therapeutics is a Healthcare company based in Strasbourg (France) founded in 2008. GPCR-targeted drug candidates for immuno-oncology and inflammation are developed. Domain Therapeutics has raised $51.19 million across 6 funding rounds from investors including Banque Populaire, Caisse D Epargne and CIC. Domain Therapeutics has completed 2 acquisitions, including NEUROFIT and Prestwick Chemical. Its chief executive, as recorded, is Sean A MacDonald. Domain Therapeutics offers products and services including DT-9081, DT-7012, and DT-9046. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.

Company details

Developer of GPCRtargeted immunooncology and inflammation drug candidates. It offers small molecule and antibody therapeutics targeting G proteincoupled receptors involved in immune suppression and tumor microenvironment modulation. Its proprietary platform supports the identification and validation of novel GPCR targets. Key programs focus on oral EP4 receptor antagonists for solid tumors, Tregdepleting antiCCR8 antibodies, and PAR2 negative allosteric modulators for inflammatory diseases. The pipeline emphasizes precision therapy guided by biomarker strategies, aiming to enhance immune response and address resistance mechanisms in cancer and inflammation.

Key Metrics
  • Annual Revenue
    $7.71 M (USD)
    -31
    as on Dec 31, 2023
  • Net Profit
    -$14.24 M (USD)
    -65
    as on Dec 31, 2023
  • EBITDA
    -$17.64 M (USD)
    -55
    as on Dec 31, 2023
  • Total Equity Funding
    $51.19M (USD)

    in 6 rounds

  • Latest Funding Round
    $42M (USD), Series A

    May 2022

  • Investors
  • Investments & Acquisitions
    NEUROFIT

    & 1 more

Products & Services of Domain Therapeutics

Domain Therapeutics offers a comprehensive portfolio of products and services, including DT-9081, DT-7012, and DT-9046.

DT-9081
Therapy

EP4 receptor antagonist for treating solid tumors.

DT-7012
Antibody

Anti-CCR8 antibody for solid tumor depletion.

DT-9046
Antagonist

Biased PAR2 antagonist for inflammation management.

Funding Insights of Domain Therapeutics

Domain Therapeutics has successfully raised a total of $51.19M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $42 million completed in May 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $51.19M
  • Total Rounds 6
  • Last Round Series A β€” $42M
  • First Round $2.82M

    (Dec 2008)

  • Investors Count 24

All 6 funding rounds of Domain Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2022$42MSeries A–Panacea Venture, CTI Life Sciences Fund
Jan 2020$6.67MDebt – Conventional––
May 2019$3.92MSeries A–Seventure Partners
–
Apr 2014$230,000Grant––
Jul 2012$2.45MSeries A–Seventure Partners
Dec 2008$2.82MSeed––
Valuation history

24 investors in total: 22 institutional and 2 angel.

Investors in Domain Therapeutics

Domain Therapeutics has secured backing from 24 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Banque Populaire, Caisse D Epargne and CIC.

All
Venture Fund
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
A life sciences venture fund is operated with global reach.
panaceaventure.com
Venture capital investments are made in life sciences companies.
ctisciences.comMontreal, Canada
Early-stage healthcare investments are made by 3B Future Health Fund.
3bfuturehealth.comLuxembourg, Luxembourg
Private equity investments are made in companies across diverse sectors.
turennecapital.comParis, France
Private equity firm focused on energy transition and sustainable investments across Europe.
omnescapital.com
Theodorus is engaged in managing investment funds for research innovation.
theodorus.beBrussels, Belgium
Biotechnology startups are incubated and funded by Viva BioInnovator.
2014vivabioinnovator.comShanghai, China
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US
seventure.frParis, France
SODIV is engaged in supporting SMEs in Grand Est.
sodiv.frMulhouse, France
Venture capital investments are managed by Auriga Partners in France.
1998aurigapartners.comParis, France
Premium access

Investor details for Domain Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Domain Therapeutics

29 people are tracked at Domain Therapeutics (10 in leadership, 11 in board & advisors, 8 in team).

NameRoleGroup
Sean A MacDonald
CEOLeadership
Clément Jodeau
Head of LegalLeadership
Marjorie Sidhoum
Director, Business DevelopmentLeadership
Asmaa Boudribila
Medical DirectorLeadership
Thibaut Brugat
Head Of PortfolioLeadership
Stanislas-Léonard Malmezat
CFOLeadership
Nathalie Lenne
VP, Strategic Portfolio ManagementLeadership
Stephan Schann
VP, ResearchLeadership
Orphée Blanchard
Head of Innovation and Immunology groupLeadership
Stanislas MALMEZAT
Chief Financial Officer - CFO - Biotech / Drug discovery / Clinical developmentLeadership
Antoine Italiano
Scientific AdvisorBoard & advisors
John Stagg
Scientific Advisory Board MemberBoard & advisors
James Huang
DirectorBoard & advisors
J. Silvio Gutkind
Scientific AdvisorBoard & advisors
Aurélie Maisner
Directeur Des Ressources HumainesBoard & advisors
Michel Bouvier
Chairman, Scientific Advisory BoardBoard & advisors
Guy Le Houillier
DirectorBoard & advisors
Emmanuel Fiessinger
DirectorBoard & advisors
Laurence Rulleau
DirectorBoard & advisors
Roberto De Ponti
DirectorBoard & advisors

9 more people are available in the full profile.

Premium access

Complete people profiles for Domain Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Domain Therapeutics

Domain Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include NEUROFIT and Prestwick Chemical.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Provides chemical screening libraries and customized medicinal chemistry services to drug developers
prestwickchemical.comIllkirch Graffenstaden, France1999Dec 2019β€’β€’β€’β€’
A preclinical CRO specializing in nervous system disorder treatments.
neurofit.comIllkirch Graffenstaden, France1996Dec 2019β€’β€’β€’β€’
Premium access

Complete acquisition details for Domain Therapeutics

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Domain Therapeutics

5 dated milestones of Domain Therapeutics across 14 years, from founding to its latest funding, stage changes and deals.

  1. Founded Domain Therapeutics is founded.
  2. Funding First funding round of $2.8M.
  3. Acquisition Acquires NEUROFIT.
  4. Acquisition Acquires Prestwick Chemical.
  5. Funding Latest funding round, Series A, of $42.0M.

Web traffic of Domain Therapeutics

The website of Domain Therapeutics (domaintherapeutics.com) receives about 2.6K visits a month.

  • Monthly visits
    2.6K

    ▼ 36% vs previous month

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Domain Therapeutics

Premium access

Complete news archive for Domain Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Domain Therapeutics

Domain Therapeutics was founded in 2008.

Domain Therapeutics is headquartered in Strasbourg, France. It is registered at Strasbourg, Grand Est, France.

Sean A MacDonald is the CEO of Domain Therapeutics, as recorded in our data.

Domain Therapeutics is a funded company, having raised a total of $51.19M across 6 funding rounds to date. The company's 1st funding round was a Seed of $2.82M, raised on Dec 2008.

Annual revenue of Domain Therapeutics is $7.71M as on Dec 31, 2023.

Developer of GPCRtargeted immunooncology and inflammation drug candidates. It offers small molecule and antibody therapeutics targeting G proteincoupled receptors involved in immune suppression and tumor microenvironment modulation. Its proprietary platform supports the identification and validation of novel GPCR targets. Key programs focus on oral EP4 receptor antagonists for solid tumors, Tregdepleting antiCCR8 antibodies, and PAR2 negative allosteric modulators for inflammatory diseases. The pipeline emphasizes precision therapy guided by biomarker strategies, aiming to enhance immune response and address resistance mechanisms in cancer and inflammation.

Domain Therapeutics offers DT-9081, DT-7012, and DT-9046.

Domain Therapeutics has made 2 acquisitions, including NEUROFIT, and Prestwick Chemical.

Domain Therapeutics has 24 investors. Key investors include Banque Populaire, Caisse D Epargne, CIC, AGF Management Limited, and Bpifrance.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available